| For medical practitioners and the general public - Cholesterol Journal Article Catalog. |
| First Page | Previous Page | Next Page | Last Page |
| Soluble fiber polysaccharides: effects on plasma cholesterol and colonic fermentation Topping, D. L. (1991), Nutr Rev 49(7): 195-203. Abstract: Many soluble-fiber polysaccharides, used as stabilizers and thickeners by the food industry, lower plasma cholesterol and slow small intestinal transit and nutrient absorption. Although nondigestible by human enzymes, these polysaccharides are fermented by the large-bowel microflora, yielding short-chain fatty acids that are absorbed and contribute to energy. The caloric yield from fiber polysaccharides needs to be quantified. Short-chain fatty acid production from soluble fibers is modified by the presence of insoluble fibers but, in total, is probably less than from other carbohydrates, e.g., resistant starch. Short-chain fatty acids do not seem to mediate effects of fiber on plasma cholesterol, but in the large bowel they exert the trophic and antineoplastic effects of dietary fiber. The mechanism for cholesterol reduction by soluble fibers relates to enhanced steroid excretion and altered fat absorption and may be a function of the viscosity of these fibers in solution. The relationships between the chemical structure of soluble polysaccharides and their documented physiologic effects are not yet clear. By using polysaccharides of defined structure and properties, it should be possible to identify those characteristics that predict physiologic actions. |
| Soluble polysaccharide and biomass of red microalga Porphyridium sp. alter intestinal morphology and reduce serum cholesterol in rats Dvir, I., R. Chayoth, et al. (2000), Br J Nutr 84(4): 469-76. Abstract: The present study investigated the effects of the red microalga Porphyridium sp. on gastrointestinal physiology and lipid metabolism in male Sprague-Dawley rats. Diets containing dietary fibre from pelleted red microalgal cells (biomass) or their sulfated polysaccharide, pectin or cellulose (control) were fed to rats for a period of 30 d. All three fibre-supplemented diets increased the length of both the small intestine and colon, with a significantly greater effect in rats fed the algal polysaccharide. The polysaccharide also increased mucosa and muscularis cross-sectional area of the jejunum, and caused hypertrophy in the muscularis layer. The algal biomass significantly lowered gastrointestinal transit time by 44% in comparison with the control rats. Serum and mucosal cholecystokinin levels were lower in rats on the pectin and polysaccharide diets, while cholecystokinin levels in rats fed algal biomass were not different from those in the control animals. In comparison with the control diet, all the experimental diets significantly lowered serum cholesterol levels (22-29%). Feeding of non-fermentable algal polysaccharide or biomass significantly increased faecal weight and bile acid excretion compared with pectin-fed or control rats. The algal polysaccharide and biomass were thus shown to be potent hypocholesterolaemic agents active at low concentrations in the diet. Both metabolic and morphological changes were observed following consumption of algae, suggesting several possible mechanisms by which the alga affects lipid metabolism. The results presented in the present study encourage the use of red microalga as a functional food. |
| Somatic cell genetic analysis of two classes of CHO cell mutants expressing opposite phenotypes in sterol-dependent regulation of cholesterol metabolism Hasan, M. T. and T. Y. Chang (1994), Somat Cell Mol Genet 20(6): 481-91. Abstract: Two different classes of hamster cell mutants (25RA cells and M1 cells) express opposite phenotypes in sterol dependent regulation. In 25RA cells, sterols added in growth medium fail to cause down-regulation of sterol synthesis rate and low density lipoprotein (LDL) receptor activity, while in M1 cells, removal of lipids from growth medium fail to cause up-regulation of sterol synthesis rate and LDL receptor activity. Cell hybridization analysis showed that the 25RA phenotype is semidominant, while the M1 phenotype is recessive. Using 25RA as the parental cells, we isolated eight independent mutant cells (DM cells) and showed that all of them belong to the same genetic complementation group as the M1 mutant, indicating that the normal (unmutated) M1 gene product(s) is required to express the 25RA phenotype. We next performed gene transfer experiments using hamster cell genomic DNAs containing the functional human M1 gene as the donor, and the double mutant cell DM7 as the recipient. The resultant transfectant cells express the 25RA cell phenotype (instead of the wild-type cell phenotype). This result, along with the results obtained from cell hybridization analysis, shows that the 25RA and M1 cell phenotypes are caused by mutations at two different genes. |
| Some evidence excluding the possibility that rat plasma cholesterol is regulated by the modification of enterohepatic circulation of steroids Saeki, S. and S. Kiriyama (1990), Monogr Atheroscler 16: 71-84. |
| Some metabolic aspects of the hypocholesterolemic effect of soybean protein in rats fed a cholesterol-free diet Saeki, S., O. Kanauchi, et al. (1990), J Nutr Sci Vitaminol (Tokyo) 36 Suppl 2: S125-31. Abstract: The present paper shows a series of experiments carried out to elucidate the possible mechanism by which soybean protein isolate (SPI) produces a lower level of plasma cholesterol than casein in rats fed a cholesterol-free diet. When the plasma cholesterol level was in a steady state characteristic of casein and SPI, SPI in the diet was substituted for casein and vice versa. Within 3 days after substitution of dietary protein, the plasma cholesterol level in each group reached a steady state level similar to that in its previous counterpart. The inherent responses of plasma cholesterol to casein and SPI were not changed by the resection of the jejunum or the ileum and the administration of cholestyramine or beta-sitosterol. The rates of the sterol synthesis in vivo of the liver and the small intestine were significantly higher in SPI-fed rats than in casein-fed rats. The hypocholesterolemic effect of SPI disappeared when Met was supplemented at a level equivalent to casein. The effects of casein and SPI were reproduced by their equivalent amino acid mixtures. The ratio of the postprandial increment of Met concentration to that of Gly concentration in the portal plasma was significantly higher when casein and its amino acid mixture were fed than when SPI and its amino acid mixture were fed. The casein-induced increase in the level of plasma cholesterol was attributed to an increase in high density lipoprotein (HDL)-cholesterol. HDL-cholesterol concentration showed the positive correlation with the lecithin:cholesterol acyltransferase activity.(ABSTRACT TRUNCATED AT 250 WORDS) |
| Sources of cholesterol during development of the rat fetus and fetal organs Jurevics, H. A., F. Z. Kidwai, et al. (1997), J Lipid Res 38(4): 723-33. Abstract: Female rats at various stages of pregnancy were injected intraperitoneally with 3Hwater; 4 h later, they were killed, the uterus was removed, and the fetuses were dissected. Lipids were isolated and fractionated by HPLC and the total amount of cholesterol in each organ, as well as radioactivity incorporated into cholesterol and cholesterol precursors, were determined. From the data for cholesterol content at each age we calculated the rate of accumulation of cholesterol during fetal development. As incorporation of label from 3Hwater takes place with a stoichiometry defined by a known biosynthetic pathway, we were also able to determine the fraction of cholesterol accumulating in each organ that had been newly synthesized. For the fetus as a whole, more than 93% of the cholesterol accumulating during development was newly synthesized. As the specific radioactivity of cholesterol in the maternal circulation was negligible (because synthesis of cholesterol by maternal liver was suppressed by inclusion of cholesterol in the diet), we conclude that the fetus synthesizes nearly all of its own cholesterol; neither the maternal circulation nor the placenta/yolk sac contribute significant amounts of cholesterol to the fetus. We were also able to quantitate trafficking of cholesterol between fetal organs. Fetal brain is responsible for the synthesis of all of its own cholesterol. In contrast, fetal liver exports cholesterol into the fetal circulation and supplies about half of the cholesterol for development of heart, lung, and kidney. |
| Sources of cholesterol for kidney and nerve during development Jurevics, H. A. and P. Morell (1994), J Lipid Res 35(1): 112-20. Abstract: Rats were injected intraperitoneally with 3Hwater; 2 h later, they were killed, dissected, and cholesterol was isolated from several tissues. Measurement of incorporated radioactivity allowed for calculation of the absolute amount of newly synthesized cholesterol appearing in a tissue. We determined the daily rate of synthesis of cholesterol in the sciatic nerve and kidney of rats at 10 time points between birth and 35 days of age. We compared this to the daily rate of accumulation of total cholesterol. For the sciatic nerve, total accumulation of cholesterol during development was always matched by accumulation of newly synthesized cholesterol, indicating that sciatic nerve synthesizes all of its own cholesterol. This was so independently of whether, at weaning, animals were placed on a cholesterol-free diet or a 2% cholesterol-containing diet. In contrast, in kidney, during the suckling period, only 25% of the accumulated cholesterol was newly synthesized; the remainder came from the circulation. Upon weaning to a 2% cholesterol-containing diet, there was increased local synthesis of cholesterol in kidney, so that within a few days about 50% was locally synthesized. If, however, the animals were weaned onto a cholesterol-free diet, there appeared to be further up-regulation of cholesterol biosynthesis in kidney; now all of the cholesterol accumulating was accounted for by that newly synthesized. Thus, the nerve is invariant with respect to self sufficiency for cholesterol; the kidney changes in this regard during development and as a function of diet. |
| Sources of cholesterol for testosterone biosynthesis in murine Leydig cells Hou, J. W., D. C. Collins, et al. (1990), Endocrinology 127(5): 2047-55. Abstract: The sources of cholesterol for testosterone production were investigated in freshly isolated murine Leydig cells. In vitro stimulation with human CG (hCG) (0.2 IU/ml) caused a 75-fold increase in testosterone production. Leydig cells contained approximately equal amounts of free and esterified cholesterol (7.8 vs. 8.7 micrograms/mg protein). The total cholesterol content of cells stimulated for 4 h with hCG was significantly decreased compared with unstimulated cells (8.4 vs. 17.6 micrograms/mg protein); both free and esterified cholesterol decreased by about 50%. In unstimulated Leydig cells incubated with 14Cacetate for 12 h, the majority of incorporated 14C was found in free and esterified cholesterol, whereas, in the hCG-stimulated cells, 80% of incorporated 14C was in testosterone. The activity of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase after 4 h in hCG-stimulated cells was 20% higher than in unstimulated cells (115.5 vs. 84.4 pmol/mg protein.min). However, by 6 h, HMG-CoA reductase activity doubled in the hCG-stimulated compared with unstimulated cells. By 12 h, HMG-CoA reductase activity in hCG-stimulated cells was 4 times the preincubation level and 8 times the 12-h level in unstimulated cells. HMG-CoA reductase activity induced by hCG was blocked by aminoglutethimide, an inhibitor of the cholesterol side-chain cleavage enzyme. Lovastatin, a potent inhibitor of HMG-CoA reductase, had no effect on unstimulated or hCG-stimulated testosterone production during a 12-h incubation. Murine high density lipoproteins (mHDL) increased HMG-CoA reductase activity in both unstimulated (29%) and hCG-stimulated (20%) cells. During a 6 h incubation, mHDL increased hCG-stimulated testosterone production by 20%, but had no effect on unstimulated testosterone production. These results suggest that murine Leydig cells store enough cholesterol and cholesteryl esters to support testosterone production for at least 12 h in vitro. Although mHDL does not have a major stimulatory effect on testosterone biosynthesis, it may be involved in the regulation of de novo cholesterol synthesis. |
| Sources of fat, fatty acids, and cholesterol in the diets of adolescents Witschi, J. C., A. L. Capper, et al. (1990), J Am Diet Assoc 90(10): 1429-31. |
| Sources of triacylglycerol accumulation in livers of rats fed a cholesterol-supplemented diet Liu, C. H., M. T. Huang, et al. (1995), Lipids 30(6): 527-31. Abstract: The source of free fatty acids (FFA) and the pathways contributing to the accumulation of neutral fats in livers of rats fed a cholesterol-enriched diet were investigated in this report. Supplementation with 1% cholesterol in the diet for four weeks resulted in hepatomegaly in the rats. The contents of cholesterol and triacylglycerols (TG) per gram liver measured in rats fasted overnight increased by 48 mg (approximately tenfold) and 66 mg (approximately fourfold), respectively. The activities of glycerophosphate acyltransferase and diacylglycerol acyltransferase, the two key enzymes for TG synthesis in liver microsomes, were found to increase by 23 and 19%, respectively, in the cholesterol-fed rats. The secretion of plasma TG present predominantly in very low density lipoprotein was found to decrease by approximately 30%. The incorporation of tritium from tritiated water in liver FFA increased by twofold in rats fed the cholesterol-supplemented diet, whereas the activity of CPT I in liver mitochondria decreased by 23%. The uptake of plasma FFA in vivo in livers of fasted rats maintained on the cholesterol-supplemented diet decreased by 60%. Our data thus indicate that the excess TG accumulated in livers of rats fed the cholesterol-enriched diet resulted from increased synthesis and decreased secretion of TG. To meet the demand of fatty acids for this purpose, de novo lipogenesis increased, whereas beta-oxidation decreased. Although difference in the uptake of extrahepatic FFA may be discounted, a difference in the uptake of chylomicron remnants between the control and cholesterol-fed rats may not be ruled out. |
| Sources of variance in daily physical activity levels in the seasonal variation of blood cholesterol study Matthews, C. E., J. R. Hebert, et al. (2001), Am J Epidemiol 153(10): 987-95. Abstract: The authors examined sources of variance in self-reported physical activity in a cohort of healthy adults (n = 580) from Worcester, Massachusetts (the Seasonal Variation of Blood Cholesterol Study, 1994-1998). Fifteen 24-hour physical activity recalls of total, occupational, and nonoccupational activity (metabolic equivalent-hours/day) were obtained over 12 months. Random effects models were employed to estimate variance components for subject, season, day of the week, and residual error, from which the number of days of assessment required to achieve 80% reliability was estimated. The largest proportional source of variance in total and nonoccupational activity was within-subject variance (50-60% of the total). Differences between subjects accounted for 20-30% of the overall variance in total activity, and seasonal and day-of-the-week effects accounted for 6% and 15%, respectively. For total activity, 7-10 days of assessment in men and 14-21 days of assessment in women were required to achieve 80% reliability. For nonoccupational activity, 21-28 days of assessment were required. This study is among the first to have examined the sources of variance in daily physical activity levels in a large population of adults using 24-hour physical activity recall. These findings provide insight for understanding the strengths and limitations of short term and long term physical activity assessments employed in epidemiologic studies. |
| Soy and cholesterol reduction: clinical experience Sirtori, C. R., M. R. Lovati, et al. (1995), J Nutr 125(3 Suppl): 598S-605S. Abstract: A role of vegetable proteins in reducing coronary artery disease risk was postulated as long ago as 1909 in Russia by Ignatowski. The protein hypothesis of atherosclerosis was pursued by many investigators, who studied the possible role of animal vs. vegetable protein in modifying concentrations of plasma lipids and thus cardiovascular disease risk. Over the past 20 y, our research group has examined the potential of a diet based on vegetable protein (in most cases, textured vegetable protein, or TVP) to modify plasma lipid concentrations. Textured products allow administration of a large percentage of protein (up to 50-60% in the product) and are available in a variety of food items. We studied > 1000 patients. An extensive review of the literature indicates that similar findings have been reported by others when administering TVP or TVP-like items to subjects with well-characterized hypercholesterolemia (Fredrickson type II). Data are less consistent for treatment of patients with marginal hypercholesterolemia or hypercholesterolemia already corrected by a standard diet before administration of soy products. The TVP diet, is, however, effective when normolipidemic individuals are made hypercholesterolemic by dietary cholesterol administration. These and other findings suggest that, in man, similar to experimental animals, soy protein may in some way up-regulate LDL receptors depressed by hypercholesterolemia or by dietary cholesterol administration. |
| Soy consumption and cholesterol reduction: review of animal and human studies Carroll, K. K. and E. M. Kurowska (1995), J Nutr 125(3 Suppl): 594S-597S. Abstract: Animal proteins such as casein are more hypercholesterolemic than soy protein or other plant proteins when fed to rabbits in low-fat, cholesterol-free, semipurified diets. A casein-amino acid mixture produces a hypercholesterolemia similar to that of casein. This appears to be mainly due to lysine and methionine, although other essential amino acids probably contribute to the effect. Arginine appeared to counteract the hypercholesterolemic effects of other essential amino acids. Soy protein gave a lower level of serum cholesterol in rabbits than did a soy protein-amino acid mixture, suggesting the presence of factors in soy protein that counteract the effects of hypercholesterolemic amino acids. Soy protein is also less hypercholesterolemic than casein in other animal species, particularly when the diet contains cholesterol, and substitution of soy protein for animal protein in the diet reduces the concentration of serum cholesterol in humans. This effect is somewhat variable but is generally greater in hypercholesterolemic than in normocholesterolemic subjects. The differing effects of dietary proteins on serum cholesterol concentrations in humans and in rabbits are primarily due to changes in LDL cholesterol, and the hypercholesterolemia produced by dietary casein is associated with down-regulation of hepatic LDL receptors. |
| Soy intake and blood cholesterol concentrations: a cross-sectional study of 1033 pre- and postmenopausal women in the Oxford arm of the European Prospective Investigation into Cancer and Nutrition Rosell, M. S., P. N. Appleby, et al. (2004), Am J Clin Nutr 80(5): 1391-6. Abstract: BACKGROUND: Clinical trials have suggested that the intake of soy protein reduces blood cholesterol. Few studies have explored this relation in subjects who consume soy as part of their regular diet. OBJECTIVE: In this study, we investigated whether blood cholesterol concentrations are related to the intake of soyfoods in a cohort comprising subjects with a wide variation in soy intake. DESIGN: This cross-sectional study included 1033 pre- and postmenopausal women selected from the Oxford arm of the European Prospective Investigation into Cancer and Nutrition. The sample included 361 nonvegetarians, 570 vegetarians, and 102 vegans. Their dietary intake was assessed by using a food-frequency questionnaire. Anthropometric data, medical history, and lifestyle information were obtained with the use of a questionnaire, blood samples were obtained, and plasma total, LDL-, and HDL-cholesterol concentrations were measured. RESULTS: Soy-protein intake was inversely associated with total and LDL-cholesterol concentrations and with the ratio of total to HDL cholesterol but not with HDL-cholesterol concentrations. Mean plasma LDL-cholesterol concentrations in women with a soy-protein intake >/=6 g/d was 12.4% lower than that in women who consumed <0.5 g/d (P < 0.001). CONCLUSION: Moderate intakes of soyfoods as part of a regular diet are associated with favorable blood cholesterol concentrations. |
| Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans Zhuo, X. G., M. K. Melby, et al. (2004), J Nutr 134(9): 2395-400. Abstract: Clinical trials have noted hypocholesterolemic effects of soy protein intake, but the components responsible are not known. This meta-analysis of 8 randomized controlled trials was conducted to more precisely evaluate the effects of isoflavones on blood LDL cholesterol concentration independently of soy protein level. PubMed was searched for English-language "randomized controlled trial" articles published from 1966 to 2003 that described the effects of soy protein isolate (SPI) intake with measured isoflavone levels on blood lipids in humans using the search terms "soy protein," "isoflavones," and "cholesterol." From 31 articles identified by the search, 8 articles (with 10 low vs. high isoflavone comparisons) were selected for the meta-analysis. Subjects in each comparison consumed similar dietary fat, cholesterol, and fiber; the reported body weight of subjects did not change significantly during treatment. Serum LDL cholesterol concentration in subjects who consumed SPI (mean 50 g/d) with high isoflavone content (mean intake 96 mg/d) decreased by 0.15 mmol/L (95% CI: 0.08 to 0.23 mmol/L; P < 0.0001) compared with those who consumed the same SPI level with low isoflavone content (mean intake 6 mg/d). Decreases in serum LDL cholesterol concentration in hypercholesterolemic and normocholesterolemic subjects were 0.18 mmol/L (95% CI: 0.01 to 0.35 mmol/L; P = 0.03) and 0.14 mmol/L (95% CI: 0.06, 0.23 mmol/L; P = 0.0008), respectively. With identical soy protein intake, high isoflavone intake led to significantly greater decreases in serum LDL cholesterol than low isoflavone intake, demonstrating that isoflavones have LDL cholesterol-lowering effects independent of soy protein. |
| Soy leaf lowers the ratio of non-HDL to HDL cholesterol in hamsters Ho, H. M., L. K. Leung, et al. (2003), J Agric Food Chem 51(16): 4554-8. Abstract: The present study was to examine effect of soy leaf powder (SLP) and soy leaf ethanol extract (SLEE) on serum lipoproteins in hamsters. The control group was fed a semisynthetic diet containing 0.1% cholesterol, while the tested groups were maintained on the same diet but supplemented with 3% SLP or the equivalent amount of SLEE derived from 3% SLP for 4 weeks. SLP supplementation led to a trend of lowering serum total cholesterol (TC) and nonhigh density lipoprotein cholesterol (non-HDL-C), with HDL-C being unaffected, whereas incorporation of SLEE into the diet led to an elevated level of HDL-C and a lower level of non-HDL-C with TC being unchanged. Both SLP and SLEE supplementation caused favorably a decrease in the ratio of non-HDL-C to HDL-C. The present results demonstrate that not only soybean seeds but also soy leaves are cardioprotective, by favorably modulating serum lipid profile. |
| Soy lecithin reduces plasma lipoprotein cholesterol and early atherogenesis in hypercholesterolemic monkeys and hamsters: beyond linoleate Wilson, T. A., C. M. Meservey, et al. (1998), Atherosclerosis 140(1): 147-53. Abstract: The current study was designed to investigate the hypocholesterolemic and anti-atherogenic properties of soy lecithin beyond its fatty acid content. In experiment 1, 18 cynomolgus monkeys were divided into three groups of six and fed diets which approximated either the average American diet (AAD), the American Heart Association (AHA) Step I diet, or a modified AHA (mAHA) Step I diet containing 3.4% soy lecithin for 8 weeks. Plasma samples were collected from food-deprived monkeys and analyzed for total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), very low- and low-density lipoprotein cholesterol (non-HDL-C), and triglyceride (TG) concentrations. Group comparisons revealed that monkeys fed the mAHA Step 1 diet had significantly lower plasma TC (-46%) and non-HDL-C (-55%) levels compared to the AAD diet, whereas monkeys fed the AHA Step 1 diet had lesser reductions in plasma TC (-21%) and non-HDL-C (-18%) levels. The monkeys fed the mAHA Step I diet had significantly lower plasma TC (-32%) and non-HDL-C (-45%) compared to the monkeys fed the AHA step diet. Also, only the mAHA Step I diet significantly reduced pre-treatment plasma TC and non-HDL-C levels by - 39 and -51% respectively with no significant effect on plasma HDL-C or TG levels. In experiment 2, 45 hamsters were divided into three groups of 15 and fed the following three modified non-purified diets for 8 weeks: a hypercholesterolemic diet (HCD) containing 10%, coconut oil and 0.05%, cholesterol, HCD plus 3.4%, soy lecithin (+SL), or the HCD with added levels of linoleate and choline equivalent to the +SL diet but no lecithin (-SL). Plasma lipids were determined as in experiment 1 and aortas were perfusion-fixed and Oil Red O stained for morphometric analyses of fatty streak area. Relative to the HCD group, the +SL-treated hamsters had significantly lower plasma TC (-58%), non-HDL-C (-73%) and aortic fatty streak area (-90%). Relative to the -SL group, hamsters fed the +SL diet had significantly lower plasma TC (-33%), non-HDL-C (-50%) and significantly reduced aortic fatty streak area (-79%). In conclusion, the first experiment suggests that the cholesterol-lowering efficacy of the AHA Step I diet can be enhanced with the addition of soy lecithin without reducing plasma HDL-C levels. whereas the second experiment suggest that the hypocholesterolemic, and in particular, the anti-atherogenic properties of soy lecithin cannot be attributed solely to its linoleate content. |
| Soy protein concentrate and isolated soy protein similarly lower blood serum cholesterol but differently affect thyroid hormones in hamsters Potter, S. M., J. Pertile, et al. (1996), J Nutr 126(8): 2007-11. Abstract: There is a wide variation in the hypocholesterolemic response to ingestion of soy protein in humans. One possible explanation is that the different soy protein preparations used contain different spectra of biologically active components. This could affect a number of indices including thyroid hormone status. An increased level of thyroxine has been proposed as an underlying mechanism of the hypocholesterolemic effect of soy protein. The objective of this study was to determine if serum cholesterol and thyroid hormone concentrations differed because of feeding soy protein from different sources. Twenty-nine male weanling golden Syrian hamsters were fed rations containing 25 g/100 g protein from either isolated soy protein (ISP), soy protein concentrate (SPC) or casein for 35 d. Serum total cholesterol concentrations were lower in hamsters fed ISP and SPC compared with those fed casein (P < 0.05). No differences in cholesterol concentrations were observed in lipoprotein fractions. Serum thyroxine and free thyroxine were greater only in hamsters fed ISP than in those fed casein (P < 0.05), whereas triiodothyronine concentrations were higher in casein-fed than in SPC-fed hamsters (P < 0.05). Results indicate that protein from ISP and SPC are both effective in lowering blood cholesterol concentrations, whereas only ISP increases thyroxine concentrations. Therefore, it appears unlikely that modulation of thyroid hormone status is responsible for the cholesterol-lowering effect of soy protein. |
| Soy protein enhances the cholesterol-lowering effect of plant sterol esters in cholesterol-fed hamsters Lin, Y., G. W. Meijer, et al. (2004), J Nutr 134(1): 143-8. Abstract: This study aimed to investigate whether the combination of plant sterol esters (PSE) with soy protein or soy isoflavones may have extra cholesterol-lowering effects. Male hamsters (n=20/group) were fed diets containing (g/100 g diet) (A) 20 casein (control), (B) 0.24 PSE, (C) 20 intact soy protein (replacing casein), (D) 0.02 soy isoflavones, (E) 0.24 PSE plus 20 soy protein (replacing casein), or (F) 0.24 PSE plus 0.02 soy isoflavones, for 5 wk. All diets contained 0.08 g cholesterol/100 g diet. Compared with the control diet, the PSE and soy protein diets significantly lowered the plasma total cholesterol concentration by 13% (P<0.05) and 9% (P<0.05), respectively, whereas the isoflavone diet (D) had no effect. The combination of PSE and soy protein (diet E) decreased plasma total cholesterol by 26% (P<0.05). The decrease in plasma cholesterol concentration was mainly in the non-HDL fraction. In addition, the combination of PSE and soy protein significantly decreased plasma triacylglycerol concentration (37%, P<0.05) and reduced cholesterol accumulation in the liver. The abundance of hepatic LDL-receptors was not influenced by any of the test diets. PSE selectively increased fecal excretion of neutral sterols by 190% (P<0.05), whereas soy protein increased fecal excretion of neutral sterols and bile acids by 66% (P<0.05) and 130% (P<0.05), respectively. The combination of PSE and soy protein increased the fecal excretion of neutral sterols and bile acids compared with PSE and soy protein alone. In conclusion, the combination of PSE and soy protein more dramatically lowers plasma lipids than the individual ingredients. |
| Soy protein hydrolyzate with bound phospholipids reduces serum cholesterol levels in hypercholesterolemic adult male volunteers Hori, G., M. F. Wang, et al. (2001), Biosci Biotechnol Biochem 65(1): 72-8. Abstract: This study was done to evaluate the effects of soy protein hydrolyzate with bound phospholipids (c-SPHP), on the serum cholesterol levels in hypercholesterolemic subjects over a three-month period. Subjects were Taiwanese adult male volunteers whose serum total cholesterol levels were above 220 mg/dl. Twenty-one subjects were divided into three groups randomly, and each group was given c-SPHP zero, 3, or 6 g per day. Test diets were orally administered in a powdered drink form that contained c-SPHP or casein hydrolyzate (placebo). The subjects were given the test diet four times daily. The study consisted of a two-week pre-feeding period, a three-month feeding period, followed by a two-week post-feeding period. After 3 months of c-SPHP administration, 3 g per day, serum total cholesterol decreased significantly from the initial level (15.0%, p<0.01) and compared with the placebo group (p<0.05). Furthermore, LDL-cholesterol decreased significantly (27.7%, p<0.01) and the LDL/HDL ratio also decreased significantly (47.4%, p<0.01) from the initial levels. These effects of c-SPHP were dose-dependent. This study suggests that c-SPHP has remarkable improving effects on the serum cholesterol levels in hypercholesterolemic subjects. |